Great advances in molecular biology, genetics and imaging serve to enhance the desire to develop multi-level and multi-scale models for "personalized medicine" but they remain very challenging for high prevalence, high impact childhood onset neuropsychiatric disorders. We currently have the capacity to develop innovative, effective and efficient clinical decision support models, while also creating ...